openPR Logo
Press release

Klebsiella Pneumoniae Infections Treatment Market: Technological Advancements, Evolving Industry Trends and Insights 2014 - 2020

11-10-2016 01:54 PM CET | Health & Medicine

Press release from: TMR

Klebsiella Pneumoniae Infections Treatment Market:

Klebsiella pneumoniae infections are usually hospital acquired and patients with compromised defense mechanisms are more prone to these infections. Klebsiella pneumoniae is a pathogenic strain of genus Klebsiella of Enterobacteriaceae and is present in the normal flora of the respiratory, intestinal, and urinogenital tracts of humans. Although this bacteria is essential for normal bowel health and functioning, serious infection occurs when it gets outside the gut. According to the Centers for Disease Control and Prevention (CDC), more than 2 million patients suffer from nosocomial infections annually out of which 100,000 people die. Klebsiella pneumonia contributes to 8% of overall nosocomial infections. Normal pneumonia can be resolved effectively with medications, but Klebsiella pneumonia causes lung destruction and abscesses in many cases resulting into higher mortality rate. In Klebsiella pneumonia, the mortality rate is above 50% which increases to 90% in cases which remain untreated.

Read Full Report: http://www.transparencymarketresearch.com/klebsiella-pneumoniae-infections-treatment.html

Cephalosporins are among the most widely used class of drugs for treating Klebsiella infections and are often prescribed as monotherapy or in conjunction with aminoglycosides. Some of the prominent antibiotics found to be active against Klebsiella pneumoniae include moxifloxacin, ofloxacin, levofloxacin, ceftriaxone, betamethasone, cefepime, meropenem, terizidone, cefixime, tobramycin, and gemifloxacin. Today, several antibiotics are used to treat numerous infectious diseases caused by pathogenic microbes. However, many such medicines are becoming ineffective as the pathogenic microorganisms are becoming resistant to evolve themselves into multi drug resistant (MDR) strains. The strains of Klebsiella pneumoniae which produce Klebsiella pneumoniae carbapenemases (KPCs) are increasingly becoming common and are capable of hydrolyzing broad spectrum beta-lactam antibiotics including penicillings, and carbapenams. Klebsiella species can easily become resistant to carbapenems and unfortunately these are the only last resort antibiotics against gram-negative Klebsiella pneumonia. At present, tigecycline and polymixins (particularly polymixin B) are the only useful drugs in treating KPC producing bacteria. There is a great need of medicines which can treat the infectious strains of Klebsiella genus.

Widespread research activities are underway to find out better therapy for Klebsiella pneumonia infections, however only modest success has been achieved until date. A few promising drugs and treatment procedures are expected to bring paradigm shift in the treatment of Klebsiella pneumonia infections. Some of the drugs in various stages of drug development include CB-618, RX-04, CB-027, SM-295291, SM-369926, SGX-942, NAB-741, NAB-7061, IBN-1, and PMBN-fMLF.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2859

In a recent development in the market, Tetraphase Pharmaceuticals, Inc. was awarded with USD 67 million for development of its pipeline drug TP-434. This clinical stage drugs is a potent antibiotic against multi drug resistant (MDR) gram negative microorganism and can provide effective treatment in Klebsiella pneumoniae infection. Earlier in 2011, Rib-X Pharmaceuticals, Inc. and Sanofi S.A. had signed an exclusive worldwide agreement for research collaboration on RX-04 development program. This program is aimed at breaking ground in antibiotic discovery through developing new class of antibiotics for treating MDR pathogenic infections. Such kind of ongoing research activities by several companies for bringing new drugs in the market provide good market opportunity for these companies in the near future.

Some of the key players in the global Klebsiella pneumoniae infection treatment market with drugs in pipeline include Arsanis Biosciences GmbH, Cubist Pharmaceuticals, Inc., Cantab Biopharmaceuticals Ltd., FOB Synthesis, Inc., Melinta Therapeutics, Inc., Northern Antibiotics Oy, Phico Therapeutics Ltd., Dainippon Sumitomo Pharma Co. Ltd., Procarta Biosystems Ltd., Pfizer, Inc., Soligenix, Inc., Rib-X Pharmaceuticals, Inc., Trana Discovery, Inc., and Tetraphase pharmaceuticals, Inc.

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Klebsiella Pneumoniae Infections Treatment Market: Technological Advancements, Evolving Industry Trends and Insights 2014 - 2020 here

News-ID: 380538 • Views:

More Releases from TMR

Emerging Opportunities in Logistics Market with Current Trends Analysis
Emerging Opportunities in Logistics Market with Current Trends Analysis
The global Logistics market is estimated to attain a valuation of US$ 15,273.21 Bn by the end of 2027, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 4.5% during the forecast period, 2019-2027. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of the
Energy Measurement IC Market is expected to reach US$ 8.39 Bn by the end of 2031
According to a Transparency Market Research (TMR) research report, the global energy measurement ic market is likely to expand at a CAGR of 7.4% during the forecast period, 2022 to 2031. This suggests that the market is expected to reach US$ 8.39 Bn by the end of 2031. The study on the energy measurement ic market adopts rigorous and systematic research approaches to understand the growth dynamic of the market. The
STATCOM UPS Market to Register Double Digit Growth Rate of 16% CAGR by 2024
Over the last decade, rising number of industries and utilities are opting for static synchronous compensator or STATCOM UPS instead of static VAR compensator or SVC UPS. Low harmonic emission coupled with high speed of response is accentuating the expansion of India STATCOM UPS market now and in times to come. Playing a crucial role in voltage control and compensation of reactive power, STATCOM UPS is likely to keep its
Thin Wafer Processing and Dicing Equipment Market US$692.5 mn by 2024 - TMR
Transparency Market Research (TMR) estimates that the global thin wafer processing and dicing equipment market has a highly consolidative landscape. Disco Corp. accounted for largest share of 56.4% in 2015 and likely to be dominant in the coming years. This is creating monopoly in the thin wafer processing and dicing equipment market in terms of competitive presence. The other key players such as EV Group, Plasma-Therm LLC, Lam Research Corp,

All 5 Releases


More Releases for Klebsiella

Klebsiella Pneumoniae Infections Market Analysis, Opportunity, Research Report & …
Klebsiella Pneumoniae Infections Market Report Overview:         Report Attribute Details Base Year
Klebsiella Testing Market Growth Analysis Report 2022 to 2030 | CAGR 7.1%
𝗧𝗵𝗲 𝗚𝗹𝗼𝗯𝗮𝗹 𝗞𝗹𝗲𝗯𝘀𝗶𝗲𝗹𝗹𝗮 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗜𝘀 𝗘𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗧𝗼 𝗚𝗿𝗼𝘄 𝗔𝘁 𝗔 𝗖𝗔𝗚𝗥 𝗢𝗳 7.1% 𝗗𝘂𝗿𝗶𝗻𝗴 𝗧𝗵𝗲 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝗣𝗲𝗿𝗶𝗼𝗱. 𝗞𝗹𝗲𝗯𝘀𝗶𝗲𝗹𝗹𝗮 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄: Global Klebsiella Testing Market 2022-2030, report discovers comprehensive insights on key manufacturers with share information, market size and projection, key dynamics, growth factors, and new company profiles. The report provides detailed information about the market overview, prevalent trends, demand, and recent developments impacting the market growth in the coming
Klebsiella Infections Therapeutics- Pipeline Analysis 2018, Clinical Trials & Re …
Klebsiella infections include different types of infections like bloodstream infections; pneumonia; wound or surgical site infections; and meningitis, caused by the Klebsiella bacteria. The symptoms associated with these infections are high fevers, chills, cough, and shortness of breath. Download the sample report @ https://www.pharmaproff.com/request-sample/1065 Hospitalized patients undergoing treatment for other conditions may be susceptible to these infections. In healthcare settings, patients who require long courses of antibiotics, or are treated with
Klebsiella Pneumoniae Infections Market Symptoms, Consulting Services, Epidemiol …
Klebsiella Pneumoniae Infections Market Epidemiology outlays comprehensive Insight of the disease, historical & forecasted epidemiology as well as the market trends of Klebsiella Pneumoniae Infections Industry. The Report provides a detailed picture of the current treatment practices, emerging drugs, a market share of the individual therapies, current and forecasted market size of Klebsiella Pneumoniae Infections. The Klebsiella Pneumoniae Infections Market Report also covers current treatment practice/algorithm, market drivers, market barriers and
Klebsiella pneumoniae Infections Market : Potential and Niche Segments, Geograph …
ReportBazzar has released its latest research-based report entitled ‘Klebsiella pneumoniae Infections’ market. This report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Klebsiella pneumoniae Infections market. The report also provides a detailed analysis of key trends and latest technologies, playing a prominent role in the Klebsiella pneumoniae Infections market growth. It takes into account aspects such as drivers,
Klebsiella pneumoniae Infections (Infectious Disease) Pipeline Forecast Report, …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2017, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape. Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic